201 related articles for article (PubMed ID: 22815544)
1. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA.
Peters HP; Rumjon A; Bansal SS; Laarakkers CM; van den Brand JA; Sarafidis P; Musto R; Malyszko J; Swinkels DW; Wetzels JF; Macdougall IC
Nephrol Dial Transplant; 2012 Oct; 27(10):3923-9. PubMed ID: 22815544
[TBL] [Abstract][Full Text] [Related]
2. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
[TBL] [Abstract][Full Text] [Related]
3. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients.
Ford BA; Eby CS; Scott MG; Coyne DW
Kidney Int; 2010 Oct; 78(8):769-73. PubMed ID: 20668427
[TBL] [Abstract][Full Text] [Related]
4. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation.
Xu Y; Ding XQ; Zou JZ; Liu ZH; Jiang SH; Chen YM
J Int Med Res; 2011; 39(5):1961-7. PubMed ID: 22118000
[TBL] [Abstract][Full Text] [Related]
5. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
6. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
7. Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients?
Brătescu LO; Bârsan L; Munteanu D; Stancu S; Mircescu G
J Ren Nutr; 2010 Sep; 20(5 Suppl):S77-83. PubMed ID: 20797577
[TBL] [Abstract][Full Text] [Related]
8. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
Tessitore N; Girelli D; Campostrini N; Bedogna V; Pietro Solero G; Castagna A; Melilli E; Mantovani W; De Matteis G; Olivieri O; Poli A; Lupo A
Nephrol Dial Transplant; 2010 Dec; 25(12):3996-4002. PubMed ID: 20538788
[TBL] [Abstract][Full Text] [Related]
9. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.
Valenti L; Girelli D; Valenti GF; Castagna A; Como G; Campostrini N; Rametta R; Dongiovanni P; Messa P; Fargion S
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1331-7. PubMed ID: 19541813
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
[TBL] [Abstract][Full Text] [Related]
11. Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients.
Sany D; Elsawy AE; Elshahawy Y
Saudi J Kidney Dis Transpl; 2014 Sep; 25(5):967-73. PubMed ID: 25193892
[TBL] [Abstract][Full Text] [Related]
12. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
[TBL] [Abstract][Full Text] [Related]
13. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
[No Abstract] [Full Text] [Related]
14. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
Nephrol Dial Transplant; 2013 Dec; 28(12):3062-71. PubMed ID: 23147161
[TBL] [Abstract][Full Text] [Related]
16. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders.
Kroot JJ; Laarakkers CM; Geurts-Moespot AJ; Grebenchtchikov N; Pickkers P; van Ede AE; Peters HP; van Dongen-Lases E; Wetzels JF; Sweep FC; Tjalsma H; Swinkels DW
Clin Chem; 2010 Oct; 56(10):1570-9. PubMed ID: 20739637
[TBL] [Abstract][Full Text] [Related]
17. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation.
Malyszko J; Malyszko JS; Mysliwiec M
Ren Fail; 2009; 31(7):544-8. PubMed ID: 19839848
[TBL] [Abstract][Full Text] [Related]
18. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations.
Valenti L; Dongiovanni P; Motta BM; Swinkels DW; Bonara P; Rametta R; Burdick L; Frugoni C; Fracanzani AL; Fargion S
Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):683-90. PubMed ID: 21183736
[TBL] [Abstract][Full Text] [Related]
19. Serum prohepcidin levels in chronic inflammatory bowel diseases.
Nagy J; Lakner L; Poór VS; Pandur E; Mózsik G; Miseta A; Sipos K
J Crohns Colitis; 2010 Dec; 4(6):649-53. PubMed ID: 21122575
[TBL] [Abstract][Full Text] [Related]
20. Validation of a competitive ELISA assay for the quantification of human serum hepcidin.
Dahlfors G; Stål P; Hansson EC; Bàràny P; Sisowath C; Onelöv L; Nelson D; Eggertsen G; Marmur J; Beshara S
Scand J Clin Lab Invest; 2015; 75(8):652-8. PubMed ID: 26264426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
